Elixie

Elixie is an innovative Israeli biotech company, set to transform symptom relief for people with chronic conditions through advanced medicinal cannabis solutions.

The company develops cutting-edge oral medicinal cannabis products designed to provide effective, reliable symptomatic relief.
Elixie’s products are based on a patented, clinically validated NANO-Tech drug delivery system that overcomes the challenges of poor oral absorption of cannabinoids, ensuring enhanced bioavailability and consistent therapeutic outcomes.

With a strong focus on improving quality of life for patients, Elixie combines biotechnology innovation with rigorous clinical validation to deliver safe, effective formulations tailored for chronic conditions.

Elixie plans to launch its products in Australia in the second half of 2025 and is actively seeking local partners to support market entry and distribution. The company is committed to building strong collaborations that will enable access to its advanced medicinal cannabis solutions for patients across the region.

With its headquarters and R&D centre in Israel, Elixie brings together scientific expertise and patient-centred innovation to deliver next-generation therapeutic solutions globally.

For more information please contact Will william.lyall@israeltrade.gov.il